Brokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) Target Price at $122.70

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $122.70.

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Piper Sandler lowered their target price on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Finally, Robert W. Baird dropped their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th.

TransMedics Group Price Performance

Shares of TMDX opened at $67.67 on Thursday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm has a market capitalization of $2.28 billion, a PE ratio of 71.99 and a beta of 2.14. The stock has a 50 day simple moving average of $70.07 and a 200 day simple moving average of $85.25. TransMedics Group has a 52-week low of $55.00 and a 52-week high of $177.37.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Quarry LP raised its stake in shares of TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares in the last quarter. National Bank of Canada FI boosted its stake in shares of TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after acquiring an additional 262 shares during the period. Atlas Capital Advisors Inc. acquired a new position in shares of TransMedics Group during the 4th quarter worth approximately $31,000. Hager Investment Management Services LLC bought a new stake in TransMedics Group in the 4th quarter valued at $33,000. Finally, Sachetta LLC acquired a new stake in TransMedics Group during the 4th quarter valued at $40,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.